JaLCDOI | 10.18926/AMO/50407 |
---|---|
FullText URL | 67_3_145.pdf |
Author | Ishihara, Setsuko| Taira, Naruto| Kawasaki, Kensuke| Ishibe, Youichi| Mizoo, Taeko| Nishiyama, Keiko| Iwamoto, Takayuki| Nogami, Tomohiro| Motoki, Takayuki| Shien, Tadahiko| Matsuoka, Junji| Doihara, Hiroyoshi| Komoike, Yoshifumi| Sato, Shuhei| Kanazawa, Susumu| |
Abstract | A high mammographic breast density is considered to be a risk factor for breast cancer. However, only a small number of studies on the association between breast density and lifestyle have been performed. A cross-sectional study was performed using a survey with 29 questions on life history and lifestyle. The breast density on mammography was classified into 4 categories following the BI-RADS criteria. The subjects were 522 women with no medical history of breast cancer. The mean age was 53.3 years old. On multivariate analysis, only BMI was a significant factor determining breast density in premenopausal women (parameter estimate, -0.403;p value, 0.0005), and the density decreased as BMI rose. In postmenopausal women, BMI (parameter estimate, -0.196;p value, 0.0143) and number of deliveries (parameter estimate, -0.388;p value, 0.0186) were significant factors determining breast density;breast density decreased as BMI and number of deliveries increased. Only BMI and number of deliveries were identified as factors significantly influencing breast density. BMI was inversely correlated with breast density before and after menopause, whereas the influence of number of deliveries on breast density was significant only in postmenopausal women in their 50 and 60s. |
Keywords | breast cancer mammographic breast density life style body mass index |
Amo Type | Original Article |
Publication Title | Acta Medica Okayama |
Published Date | 2013-06 |
Volume | volume67 |
Issue | issue3 |
Publisher | Okayama University Medical School |
Start Page | 145 |
End Page | 151 |
ISSN | 0386-300X |
NCID | AA00508441 |
Content Type | Journal Article |
language | English |
Copyright Holders | CopyrightⒸ 2013 by Okayama University Medical School |
File Version | publisher |
Refereed | True |
PubMed ID | 23804137 |
Web of Science KeyUT | 000320747900003 |
Related Url | http://ousar.lib.okayama-u.ac.jp/metadata/50646 |
JaLCDOI | 10.18926/AMO/48691 |
---|---|
FullText URL | 66_4_357.pdf |
Author | Shien, Kazuhiko| Shien, Tadahiko| Soh, Junichi| Ikeda, Hirokuni| Nogami, Tomohiro| Taira, Naruto| Doihara, Hiroyoshi| Miyoshi, Shinichiro| |
Abstract | Ectopic thymoma is considered to arise from ectopic thymus tissue deposited as a result of the abnormal mislocalization of thymus tissue during the embryonic stage. An 86-year-old man visited our hospital with chief complaints of hoarseness and a mass in his anterior neck. A preoperative needle biopsy of the mass did not yield a definitive diagnosis. A positron emission tomography (PET) study revealed heterogeneous accumulation of 18F-fluorodeoxyglucose (FDG) in the tumor. The tumor, affecting the left sternocleidomastoid muscle, the recurrent laryngeal nerve, the internal carotid vein, and the brachiocephalic vein, was resected using a combination of a collar incision in the neck and a median incision in the sternum. Immunohistochemically, the tumor was diagnosed as an ectopic thymoma of the neck. To date, only a few cases of ectopic thymoma presenting with FDG accumulation have been reported. Our experience indicates that ectopic thymoma should be kept in mind during the differential diagnosis of neck tumors with FDG accumulation appearing on PET images. |
Keywords | ectopic thymoma thyroid tumor positron emission tomography (PET) |
Amo Type | Case Report |
Publication Title | Acta Medica Okayama |
Published Date | 2012-08 |
Volume | volume66 |
Issue | issue4 |
Publisher | Okayama University Medical School |
Start Page | 357 |
End Page | 361 |
ISSN | 0386-300X |
NCID | AA00508441 |
Content Type | Journal Article |
language | English |
Copyright Holders | CopyrightⒸ 2012 by Okayama University Medical School |
File Version | publisher |
Refereed | True |
PubMed ID | 22918209 |
JaLCDOI | 10.18926/AMO/46848 |
---|---|
FullText URL | 65_4_231.pdf |
Author | Shien, Tadahiko| Doihara, Hiroyoshi| Nishiyama, Keiko| Masuda, Hiroko| Nogami, Tomohiro| Ikeda, Hirokuni| Taira, Naruto| |
Abstract | Combined low-dose therapy of oral capecitabine (Xeloda) and cyclophosphamide (XC) has been demonstrated to be useful for long-term control of lesions in patients with metastatic breast cancer (MBC) and is aimed at symptomatic alleviation and prolongation of survival. Here, a retrospective review was conducted of MBC patients administered XC at the Okayama University Hospital (OUH), to evaluate responses to XC, adverse events and time to progression (TTP). Twenty patients with MBC received XC between 2006 and 2009. With the exception of 2 elderly patients who were over the age of 70 at the initial examination, all of the patients had received prior treatment with an anthracycline and/or a taxane. No complete response (CR) cases were observed, but partial response (PR) was achieved in 6 patients (30%) and SD in 9 (45%), of whom 5 (20%) sustained SD status for >12 months. The median TTP was 6 months (range:3-27 mo.). Three patients developed Grade 3 adverse events (diarrhea, nausea and stomatitis), but no other patients developed adverse reactions causing interruption of the therapy. XC was safe even in previously treated and elderly MBC patients;moreover, it yielded remarkable clinical responses. |
Keywords | metastatic breast cancer metronomic chemotherapy |
Amo Type | Original Article |
Publication Title | Acta Medica Okayama |
Published Date | 2011-08 |
Volume | volume65 |
Issue | issue4 |
Publisher | Okayama University Medical School |
Start Page | 231 |
End Page | 237 |
ISSN | 0386-300X |
NCID | AA00508441 |
Content Type | Journal Article |
language | English |
Copyright Holders | CopyrightⒸ 2011 by Okayama University Medical School |
File Version | publisher |
Refereed | True |
PubMed ID | 21860529 |
Web of Science KeyUT | 000294236700003 |
JaLCDOI | 10.18926/AMO/31816 |
---|---|
FullText URL | fulltext.pdf |
Author | Okita, Atsushi| Saeki, Toshiaki| Aogi, Kenjiro| Osumi, Shozo| Takashima, Shigemitsu| Okita, Riki| Taira, Naruto| Kakishita, Tomokazu| Kurita, Akira| |
Abstract | Toremifene citrate is expected to prevent drug resistance in cancer patients by inhibiting p-glycoprotein activity. The safety and efficacy of combination therapy with high-dose toremifene citrate and paclitaxel were investigated. Between December 2003 and June 2004, 15 women with a mean age of 53 years old with metastatic breast cancer were enrolled. The administration schedule was 80mg/m2 of paclitaxel given on Days 1, 8, and 15, and 120mg/day of toremifene citrate orally administered starting on Day 18. On Days 32 and 39, paclitaxel was concurrently administered again. Toxicities, response rate, and time to treatment failure were assessed. All patients had been treated with endocrine or chemotherapy. Grade 3 leukopenia occurred in 2 patients on the administration of paclitaxel alone, and grade 3 febrile neutropenia occurred in 1 patient given the combination therapy. There was no grade 3 or greater non-hematological toxicity. There was no complete response and 1 partial response, producing a response rate of 6.7%. Median time to treatment failure was 2.7 months. Combination therapy of paclitaxel and toremifene was safe and well tolerated with minimal toxicity. Further clinical trials targeting patients with functional p-glycoprotein are warranted. |
Keywords | toremifene paclitaxel p-glycoprotein metastatic breast cancer |
Amo Type | Original Article |
Publication Title | Acta Medica Okayama |
Published Date | 2009-08 |
Volume | volume63 |
Issue | issue4 |
Publisher | Okayama University Medical School |
Start Page | 187 |
End Page | 194 |
ISSN | 0386-300X |
NCID | AA00508441 |
Content Type | Journal Article |
language | English |
File Version | publisher |
Refereed | True |
PubMed ID | 19727203 |
Web of Science KeyUT | 000269228400004 |
JaLCDOI | 10.18926/AMO/30755 |
---|---|
FullText URL | fulltext.pdf |
Author | Taira, Naruto| Doihara, Hiroyoshi| Oota, Tetsuya| Hara, Fumikata| Shien, Tadahiko| Takahashi, Hirotoshi| Yoshitomi, Seiji| Ishibe, Youichi| Shimizu, Nobuyoshi| |
Abstract | Human esophageal cancers have been shown to express high levels of epidermal growth factor receptor (EGFR) and a relationship between high EGFR expression and local advance, the number of lymph node metastases, life expectancy, and sensitivity to chemo-radiotherapy has been demonstrated. We examined the use of gefitinib, an orally active EGFR-selective tyrosine kinase inhibitor, as a new strategy for treatment of esophageal carcinoma. The effects of gefitinib were evaluated in monotherapy and in combination with radiotherapy in human esophageal carcinoma cell lines. Gefitinib produced a dose-dependent inhibition of cellular proliferation in all of the 8 esophageal carcinoma cell lines examined, with IC50 values ranging from 5.7 microM to 36.9 microM. In combination, gefitinib and radiotherapy showed a synergistic effect in 2 human esophageal carcinoma cell lines and an additive effect in 5 cell lines. Western blotting demonstrated that gefitinib blocked activation of the EGFR-extracellular signal-regulated kinase (Erk) pathway and the EGFR-phosphoinositide-3 kinase (PI3K)-Akt pathway after irradiation. These results suggest that further evaluation of EGFR blockade as a treatment for esophageal cancer should be performed, and that radiotherapy combined with EGFR blockade may enhance the response of esophageal carcinoma to therapy. |
Keywords | gefitinib esophageal cancer radiosensitivity epidermal growth factor receptor |
Amo Type | Article |
Publication Title | Acta Medica Okayama |
Published Date | 2006-02 |
Volume | volume60 |
Issue | issue1 |
Publisher | Okayama University Medical School |
Start Page | 25 |
End Page | 34 |
ISSN | 0386-300X |
NCID | AA00508441 |
Content Type | Journal Article |
language | English |
File Version | publisher |
Refereed | True |
PubMed ID | 16508686 |
Web of Science KeyUT | 000235538900003 |